Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
Top Cited Papers
Open Access
- 28 December 2012
- journal article
- review article
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 7 (s1) , 25-36
- https://doi.org/10.1111/irv.12047
Abstract
Please cite this paper as: McKimm-Breschkin (2012) Influenza neuraminidase inhibitors: Antiviral action and mechanisms of resistance. Influenza and Other Respiratory Viruses 7(Suppl. 1), 2536. There are two major classes of antivirals available for the treatment and prevention of influenza, the M2 inhibitors and the neuraminidase inhibitors (NAIs). The M2 inhibitors are cheap, but they are only effective against influenza A viruses, and resistance arises rapidly. The current influenza A H3N2 and pandemic A(H1N1)pdm09 viruses are already resistant to the M2 inhibitors as are many H5N1 viruses. There are four NAIs licensed in some parts of the world, zanamivir, oseltamivir, peramivir, and a long-acting NAI, laninamivir. This review focuses on resistance to the NAIs. Because of differences in their chemistry and subtle differences in NA structures, resistance can be both NAI- and subtype specific. This results in different drug resistance profiles, for example, the H274Y mutation confers resistance to oseltamivir and peramivir, but not to zanamivir, and only in N1 NAs. Mutations at E119, D198, I222, R292, and N294 can also reduce NAI sensitivity. In the winter of 20072008, an oseltamivir-resistant seasonal influenza A(H1N1) strain with an H274Y mutation emerged in the northern hemisphere and spread rapidly around the world. In contrast to earlier evidence of such resistant viruses being unfit, this mutant virus remained fully transmissible and pathogenic and became the major seasonal A(H1N1) virus globally within a year. This resistant A(H1N1) virus was displaced by the sensitive A(H1N1)pdm09 virus. Approximately 0.51.0% of community A(H1N1)pdm09 isolates are currently resistant to oseltamivir. It is now apparent that variation in non-active site amino acids can affect the fitness of the enzyme and compensate for mutations that confer high-level oseltamivir resistance resulting in minimal impact on enzyme function.Keywords
This publication has 112 references indexed in Scilit:
- In vitro selection of influenza B viruses with reduced sensitivity to neuraminidase inhibitorsClinical Microbiology & Infection, 2011
- Cluster of Oseltamivir-Resistant 2009 Pandemic Influenza A (H1N1) Virus Infections on a Hospital Ward among Immunocompromised Patients—North Carolina, 2009The Journal of Infectious Diseases, 2011
- Evidence of Person-to-Person Transmission of Oseltamivir-Resistant Pandemic Influenza A(H1N1) 2009 Virus in a Hematology UnitThe Journal of Infectious Diseases, 2011
- Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitnessJournal of Antimicrobial Chemotherapy, 2010
- Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivirTransplant Infectious Disease, 2010
- Structural and Functional Basis of Resistance to Neuraminidase Inhibitors of Influenza B VirusesJournal of Medicinal Chemistry, 2010
- Coexistence of two adamantane binding sites in the influenza A M2 ion channelProceedings of the National Academy of Sciences, 2010
- Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir ResistanceScience, 2010
- Rapid Selection of Oseltamivir‐ and Peramivir‐Resistant Pandemic H1N1 Virus during Therapy in 2 Immunocompromised HostsClinical Infectious Diseases, 2010
- Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic RepublicJournal of General Virology, 2010